NASDAQ$PACB
Pacific Biosciences of California Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Pacific Biosciences announced results for Q4 2022, with increased revenue and progress in install base and sequencing efficiency.
Pacific Biosciences reported a revenue increase in Q4 2022, driven by higher instrument revenue and consumable sales. The company saw progress in expanding its install base and improving sequencing economics. However, net losses persisted, and operating expenses remained significant.
- Q4 revenue totaled $36 million, up from $27.3 million in Q4 2021.
- Instrument revenue was $17.4 million, an increase from $11.4 million in the prior year.
- Consumables revenue reached $15.4 million, compared to $13.1 million in the prior year.
- PacBio ended the year with a preliminary installed base of 526 Sequel II/IIe systems.
Headline financials
Revenue & EPS history
Pacific Biosciences · Revenue · Quarterly
$27.4M
Revenue by segment
Pacific Biosciences · $36M total across 3 segments · Q4 2022
- Instrument Revenue$17.4M+52.6%48.3%
- Consumables Revenue$15.4M+17.6%42.8%
- Service & Other Revenue$3.2M+14.3%8.9%
Forward guidance
PacBio anticipates continued growth and innovation, expecting revenue between $170 million and $200 million in 2023.
Tailwinds
- Continued growth in instrument revenue.
- Expansion of the installed base.
- Advancements in sequencing technology.
- Increased adoption in key application areas.
- Strategic partnerships to drive market penetration.
Headwinds
- Ongoing operating losses.
- Uncertainties in the macroeconomic environment.
- Potential delays in product development.
- Competition from other sequencing platforms.
- Dependence on key suppliers and partners.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+1.6%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+4.1%
Avg return
30 days after
47%
29 / 62 earnings
Positive
+69.9%
Q3 2018
Best reaction
-27.2%
Q3 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -14.5% | -23.0% | -12.7% | |
| Q4 2025 | -7.1% | -11.4% | -27.7% | |
| Q3 2025 | -1.1% | -2.2% | +34.3% | |
| Q1 2025 | -8.4% | -8.3% | -5.0% | |
| Q4 2024 | +25.0% | +19.6% | -17.6% | |
| Q3 2024 | -13.2% | -16.6% | -23.4% | |
| Q2 2024 | +4.4% | -10.6% | -1.2% | |
| Q1 2024 | +5.4% | +32.7% | +19.6% | |
| Q4 2023 | +9.7% | -18.6% | -41.7% | |
| Q3 2023 | +20.9% | +15.2% | +48.7% | |
| Q2 2023 | -0.7% | -3.7% | -13.3% | |
| Q1 2023 | -2.8% | -0.5% | +13.6% | |
| Q4 2022 | +5.1% | -17.6% | -25.2% | |
| Q3 2022 | +2.1% | +11.8% | +31.9% | |
| Q2 2022 | +11.4% | +27.4% | -10.3% | |
| Q1 2022 | -4.5% | +2.9% | -7.1% | |
| Q4 2021 | +8.2% | +4.5% | -0.5% | |
| Q3 2021 | +6.6% | +5.3% | -22.1% | |
| Q2 2021 | +5.5% | +4.1% | +0.2% | |
| Q1 2021 | -0.2% | -3.4% | +4.7% | |
| Q4 2020 | +29.4% | +27.3% | -14.3% | |
| Q3 2020 | +16.1% | +18.2% | +62.7% | |
| Q2 2020 | -3.1% | +1.0% | +66.5% | |
| Q1 2020 | +9.4% | +11.6% | +26.7% | |
| Q4 2019 | -4.1% | -12.3% | -16.3% | |
| Q3 2019 | -2.8% | -4.8% | +3.5% | |
| Q2 2019 | +3.5% | +5.6% | +4.1% | |
| Q1 2019 | -0.3% | -1.3% | -9.6% | |
| Q4 2018 | -1.5% | -0.8% | +1.5% | |
| Q3 2018 | +69.9% | +71.2% | +75.7% | |
| Q2 2018 | +0.5% | +4.7% | +31.7% | |
| Q1 2018 | -8.7% | -6.9% | +0.8% | |
| Q4 2017 | -4.9% | -8.5% | -16.2% | |
| Q3 2017 | -27.2% | -33.9% | -27.2% | |
| Q2 2017 | +13.7% | +38.8% | +57.1% | |
| Q1 2017 | -19.4% | -20.3% | -27.2% | |
| Q4 2016 | -1.2% | -1.7% | +6.2% | |
| Q3 2016 | -20.4% | -12.7% | -17.4% | |
| Q2 2016 | +14.6% | +10.3% | +6.8% | |
| Q1 2016 | +18.2% | — | — | |
| Q4 2015 | -24.0% | — | — | |
| Q3 2015 | +9.7% | — | — | |
| Q2 2015 | -17.2% | — | — | |
| Q1 2015 | -0.5% | — | — | |
| Q4 2014 | -16.4% | — | — | |
| Q3 2014 | +11.8% | — | — | |
| Q2 2014 | +2.6% | — | — | |
| Q1 2014 | -5.6% | — | — | |
| Q4 2013 | +2.2% | — | — | |
| Q3 2013 | +0.0% | — | — | |
| Q2 2013 | +5.7% | — | — | |
| Q1 2013 | -0.4% | — | — | |
| Q4 2012 | +0.0% | — | — | |
| Q3 2012 | -5.4% | — | — | |
| Q2 2012 | +2.9% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | -12.7% | — | — | |
| Q3 2011 | -7.8% | — | — | |
| Q2 2011 | +8.9% | — | — | |
| Q1 2011 | -1.3% | — | — | |
| Q4 2010 | +2.7% | — | — | |
| Q3 2010 | +9.2% | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro